Aspirin 81 mg chewable tablets recalled due to packaging defect
Safecor Health, LLC is recalling 1,470 boxes of Aspirin 81 mg chewable tablets nationwide due to a manufacturing defect where blister card-foils are separating from the blister cavity.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall for a manufacturing defect with no reported illnesses or injuries. The hazard is a packaging integrity issue (blister separation) with no confirmed harm, consistent with a precautionary manufacturing recall scoring Moderate (2).
Plain-English summary
Safecor Health, LLC initiated a recall of 1,470 boxes of Aspirin 81 mg chewable tablets (NDC 48433-129-01) distributed nationwide. The affected product is lot number 24A0061 with an expiration date of May 23, 2026.
The recall was prompted by observations of cGMP deviations during manufacturing, specifically that some blister card-foils were separating from the blister cavity. This defect was identified through quality control processes.
Consumers who purchased this product should contact Safecor Health, LLC (www.safecorhealth.com) for information on the recall. Pharmacists and healthcare providers should identify and quarantine affected inventory.
The recalled product
- Product
- ASPIRIN (ASPIRIN 81 MG)
- Brand
- ASPIRIN
- Manufacturer
- Safecor Health, LLC
- Hazard
- blister-separation
- packaging-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# 24A0061
- exp. date 05/23/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ASPIRIN
- HighLow-dose aspirin recall due to improper storage temperature conditions
FDA (Drugs) · 2024-01-03
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27